Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study
Heart failure is a major chronic cardiovascular condition in which the heart cannot pump blood effectively enough to meet the body’s needs. It affects millions of people worldwide and is associated with frequent hospitalizations, reduced quality of life, and increased risk of death. Obesity, often measured using body mass index (BMI), is strongly linked to the development of heart failure. However, once heart failure is established, the relationship between body weight and outcomes is more complex. Some observational studies have suggested an “obesity paradox,” in which patients with higher BMI appear to have better survival, but these findings may be influenced by confounding factors such as muscle mass, illness-related weight loss, smoking, or reverse causation.
This study used Mendelian randomization, a genetic epidemiology approach, to better clarify whether higher BMI itself contributes to worse outcomes in patients with heart failure. By using genetic variants associated with BMI as instrumental variables, the researchers aimed to estimate the effect of lifelong higher BMI on mortality and major heart failure-related outcomes while reducing the bias that can affect conventional observational studies.
Why this study matters
Weight management is already an important part of cardiovascular prevention. In patients with heart failure and preserved left ventricular ejection fraction, weight loss interventions have shown benefit in some settings. But for patients with heart failure and reduced ejection fraction, the role of weight loss has been less certain. Clinicians must balance the potential benefits of lowering excess adiposity against concerns that unintentional weight loss or frailty may signal worsening disease. This study helps address that uncertainty by examining whether genetically predicted BMI is associated with harder clinical outcomes across the spectrum of left ventricular ejection fraction.
How the study was done
The investigators performed a two-sample Mendelian randomization analysis using genome-wide significant genetic loci associated with BMI. These variants served as tools to estimate the impact of higher BMI on outcomes. The outcome data came from a genome-wide association study of time-to-event clinical endpoints among patients with heart failure.
The genetic analysis included 50,636 individuals of European ancestry with established heart failure from 22 cohorts. These cohorts came from a broad range of sources: 12 heart failure trials, 1 prospective case-cohort study, 9 cohorts nested within non-heart-failure cardiovascular trials, and 1 population-based cohort from the UK Biobank. This design strengthened the analysis by drawing on multiple well-characterized patient populations.
The main exposures and outcomes were straightforward. The exposure was genetically predicted BMI. The outcomes were all-cause mortality and a composite endpoint of cardiovascular death or hospitalization for heart failure. The researchers then estimated the association between genetically predicted BMI and these outcomes, aiming to determine whether BMI is likely to play a causal role in prognosis after heart failure develops.
Key findings
The average BMI in the study population was 29.2 ± 5.8 kg/m2, which falls in the overweight range and approaches the obesity threshold on average. Over a median follow-up of 27.0 months, there were 11,454 deaths from any cause, representing 23% of participants, and 11,360 participants (22%) experienced the composite outcome of cardiovascular death or heart failure hospitalization.
Genetically predicted higher BMI was associated with worse outcomes. For every standard deviation increase in BMI, equivalent to 4.8 BMI units, the hazard ratio for all-cause mortality was 1.21 (95% confidence interval [CI]: 1.13-1.29; P = 9 × 10-8). This means that higher genetically predicted BMI was linked to a 21% higher rate of death from any cause. For the composite outcome, the hazard ratio was 1.29 (95% CI: 1.20-1.38; P = 8 × 10-13), indicating a 29% higher rate of cardiovascular death or heart failure hospitalization.
Importantly, the associations were broadly consistent across left ventricular ejection fraction subgroups. In patients with LVEF ≤40%, the hazard ratio for all-cause mortality was 1.16 (95% CI: 0.99-1.37), and for those with LVEF >40%, it was 1.20 (95% CI: 0.94-1.53). For the composite outcome, the hazard ratios were 1.30 (95% CI: 1.15-1.48) and 1.57 (95% CI: 1.29-1.91), respectively. Although the point estimates differed somewhat, the overall pattern suggested that higher BMI was associated with worse outcomes regardless of ejection fraction category.
What Mendelian randomization adds
Mendelian randomization is useful because genetic variants are assigned at conception, long before disease begins. This means they are less likely to be affected by confounding or reverse causation than weight measured after diagnosis. In practical terms, the study strengthens the argument that excess adiposity may contribute directly to poor prognosis in heart failure, rather than merely serving as a marker of other health problems.
That said, Mendelian randomization is not perfect. It relies on assumptions, including that the genetic instruments affect the outcome only through BMI and not through other biological pathways. It also cannot fully replace clinical trials. Still, when its results align with biological plausibility and clinical observation, it provides valuable evidence for causal inference.
Clinical implications
The findings support the idea that excessive body weight is not benign in heart failure. Rather than protecting against adverse outcomes, higher BMI appears to be associated with increased mortality and more frequent heart failure-related events. This has meaningful implications for care. Weight-management strategies may deserve consideration across the entire range of left ventricular ejection fraction, not only in heart failure with preserved ejection fraction.
In clinical practice, weight management should be individualized. The goal is not indiscriminate weight loss in every patient, especially not in those with cachexia, frailty, sarcopenia, or advanced disease. Instead, clinicians should assess body composition, nutritional status, physical function, congestion, and overall risk profile. For appropriate patients, interventions may include dietary counseling, physical activity, management of comorbidities such as diabetes, and, in selected cases, anti-obesity medications or bariatric approaches under specialist supervision.
Because body weight can be influenced by fluid retention in heart failure, BMI alone is an imperfect measure. Edema may inflate weight, while muscle loss may mask frailty. Therefore, a broader assessment is essential when making treatment decisions.
Practical takeaways for patients and clinicians
For patients living with heart failure, the message is not simply “lose weight at all costs.” The more accurate message is that excess adiposity may worsen outcomes, and maintaining a healthy body composition is likely important. Patients should work with their cardiology team to develop a safe, realistic plan that takes heart function, symptoms, medications, and nutritional needs into account.
For clinicians, this study adds support for integrated heart failure care that includes attention to weight, diet quality, exercise tolerance, and metabolic health. It also highlights the need for future clinical trials to define which patients benefit most from intentional weight reduction, how much weight loss is optimal, and how to preserve lean muscle mass during treatment.
Limitations
Several limitations should be kept in mind. The study population was limited to individuals of European ancestry, so the findings may not generalize perfectly to other populations. In addition, genetic prediction of BMI reflects lifelong predisposition to higher body weight, which is not identical to short-term weight changes after diagnosis. The analysis also did not directly test specific weight-loss interventions, such as medications or surgery. Therefore, the results support a causal role of adiposity but do not define the best treatment strategy for every patient.
Conclusion
In this Mendelian randomization study, higher genetically predicted BMI was associated with increased all-cause mortality and a higher risk of cardiovascular death or heart failure hospitalization among patients with heart failure. The associations were seen across left ventricular ejection fraction subgroups, suggesting that excess body weight may worsen prognosis throughout the heart failure spectrum. These findings support the potential value of thoughtful, individualized weight-management strategies in heart failure care.
As research continues, the key challenge will be translating these epidemiologic findings into practical, patient-centered interventions that improve survival, reduce hospitalizations, and preserve quality of life.
